NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis $0.81 +0.11 (+15.70%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.72▼$0.8250-Day Range$0.61▼$1.1952-Week Range$0.54▼$5.29Volume4.34 million shsAverage Volume4.70 million shsMarket Capitalization$122.98 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Seres Therapeutics alerts: Email Address Seres Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside721.0% Upside$6.67 Price TargetShort InterestBearish15.09% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews Sentiment-0.38Based on 2 Articles This WeekInsider TradingSelling Shares$3,964 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.03) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.32 out of 5 starsMedical Sector264th out of 879 stocksPharmaceutical Preparations Industry119th out of 417 stocks 3.3 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Seres Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.09% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 1.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 0.9 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,964.00 in company stock.Percentage Held by InsidersOnly 5.10% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seres Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($1.03) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Seres Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About Seres Therapeutics Stock (NASDAQ:MCRB)Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More MCRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MCRB Stock News HeadlinesJuly 3, 2024 | americanbankingnews.comStockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to SellJune 7, 2024 | globenewswire.comSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… June 6, 2024 | prnewswire.comNestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023June 6, 2024 | globenewswire.comSeres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health ScienceMay 28, 2024 | msn.comChinese firm Seres targets Audi and Tesla ahead of UK launchMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Seres Therapeutics (MCRB) and Immunocore Holdings (IMCR)May 13, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call TranscriptJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Seres Therapeutics Amidst Strong Sales Trajectory and Promising PipelineMay 9, 2024 | finance.yahoo.comSeres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comSeres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 8, 2024 | investorplace.comMCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024May 8, 2024 | msn.comSeres Therapeutics GAAP EPS of -$0.27 beats by $0.07May 8, 2024 | finance.yahoo.comSeres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue EstimatesMay 8, 2024 | businesswire.comSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | markets.businessinsider.comHere's what to expect from Seres Therapeutics's earningsMay 6, 2024 | businesswire.comSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees233Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+721.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,720,000.00 Net MarginsN/A Pretax Margin-65.18% Return on EquityN/A Return on Assets-22.44% Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick Ratio1.25 Sales & Book Value Annual Sales$126.32 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value($0.35) per share Price / Book-2.32Miscellaneous Outstanding Shares151,450,000Free Float143,724,000Market Cap$122.98 million OptionableOptionable Beta1.98 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 48)President, CEO & Director Comp: $1.02MDr. Lisa von Moltke M.D. (Age 65)Executive VP & Chief Medical Officer Comp: $725.15kDr. Teresa L. Young Ph.D. (Age 57)R.Ph., Executive VP and Chief Commercial & Strategy Officer Comp: $606.33kMs. Marella Thorell (Age 57)Executive VP & CFO Dr. David S. Ege Ph.D. (Age 49)Executive VP & Chief Technology Officer Comp: $142.71kDr. Matthew R. Henn Ph.D. (Age 49)Executive VP & Chief Scientific Officer Comp: $643.83kMr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Thomas J. DesRosier Esq. (Age 69)J.D., Chief Legal Officer, Executive VP & Secretary Comp: $719.55kMs. Caroline HoldaAssistant General CounselMore ExecutivesKey CompetitorsFibroGenNASDAQ:FGENNektar TherapeuticsNASDAQ:NKTRCassava SciencesNASDAQ:SAVALarimar TherapeuticsNASDAQ:LRMREntrada TherapeuticsNASDAQ:TRDAView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 94,510 shares on 5/20/2024Ownership: 0.062%Price T Rowe Associates Inc. MDSold 65,539 shares on 5/15/2024Ownership: 0.197%Eric D ShaffSold 2,435 sharesTotal: $2,288.90 ($0.94/share)Thomas DesrosierSold 843 sharesTotal: $792.42 ($0.94/share)Moltke Lisa VonSold 939 sharesTotal: $882.66 ($0.94/share)View All Insider TransactionsView All Institutional Transactions MCRB Stock Analysis - Frequently Asked Questions How have MCRB shares performed this year? Seres Therapeutics' stock was trading at $1.40 on January 1st, 2024. Since then, MCRB shares have decreased by 42.0% and is now trading at $0.8120. View the best growth stocks for 2024 here. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.09. When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA) and Novavax (NVAX). This page (NASDAQ:MCRB) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.